BIO-Europe Spring® 2017: Biomunex CSO defines lead compounds, early R&D plans

April 10, 2017

During BIO-Europe Spring 2017 in Barcelona, Eugene Zhukovsky, chief scientific officer at Biomunex speaks to Scrip about the company's bispecific antibody pipeline and how its candidates are different from other cancer therapies in development in this area. Zhukovsky outlines the company's early development design and the timeline for its lead compounds, which are yet to enter the clinic, in solid and hematological cancers.

 

Click here for more coverage of the activities held during BIO-Europe Spring

Previous Video
BIO-Europe Spring® 2017: Biomunex CEO on earlier deals for cancer drugs
BIO-Europe Spring® 2017: Biomunex CEO on earlier deals for cancer drugs

During the recent BIO-Europe Spring partnering conference in Barcelona, Biomunex CEO Pierre-Emmanuel Gerard...

Next Video
BIO-Europe Spring® 2017: Prexton CEO on future for novel Parkinson's therapy
BIO-Europe Spring® 2017: Prexton CEO on future for novel Parkinson's therapy

As Prexton Therapeutics prepares to move its lead compound foliglurax into Phase II trials as a symptomatic...